Iluvien 0.19mg Intravitreal Implant (Fluocinolone Acetonide Others) 0.19mg

Iluvien 0.19mg intravitreal implant contains fluocinolone acetonide, a corticosteroid used to treat chronic non-infectious uveitis affecting the posterior segment of the eye. This sustained-release implant delivers medication directly to the eye for up to 36 months. Ideal for patients requiring long-term inflammation control.

Strength

0.19mg

Pack Size

Storage

Ambient

Manufacturer / TM Owner

Alimera Sciences, Inc.

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Iluvien 0.19mg intravitreal implant is used to manage chronic non-infectious uveitis affecting the posterior segment of the eye. It helps reduce inflammation and associated symptoms such as pain, redness, and vision changes. This implant provides continuous medication delivery over an extended period.

Side Effects

The implant works by slowly releasing fluocinolone acetonide into the eye, helping to control inflammation. Patients may notice reduced eye discomfort and improved clarity in vision over time. Regular follow-ups with an eye specialist are important to monitor progress.

Precautions & Warnings

This implant is intended for use under the supervision of an eye specialist. Patients should report any signs of increased eye pressure, eye pain, or changes in vision immediately. Regular eye exams are necessary to check for potential side effects or complications.

Avoid Interactions

No direct drug interactions are expected since the medication is delivered locally to the eye. However, patients using other eye medications should inform their doctor. Systemic effects are minimal, but caution is advised in patients with a history of glaucoma or cataracts.

Frequently Asked Questions

Iluvien 0.19mg is used to treat chronic non-infectious uveitis affecting the posterior segment of the eye by reducing inflammation.

The implant releases medication for up to 36 months, providing long-term treatment for eye inflammation.

Consult your eye specialist before using Iluvien with other eye medications to avoid potential interactions.

Common side effects may include increased eye pressure or cataracts; regular monitoring is recommended.

Iluvien is prescribed based on individual medical needs; discuss your full medical history with your doctor.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.